It's hard to know as the stopped phase III trial was placebo controlled not against bisphosphonate as an active comparator plus long term safety is not clear: "The DMC noted that safety issues remain in certain selected areas and made recommendations with respect to following up on them".
Market Data 
Markets 
AI
